Revenue
2021
2022
2023
2024
2025
Senti Biosciences Holdings, Inc. (SNTI)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $22,000 | $0 | $2.0M | $3.3M | $2.3M |
| Research & development | $37.6M | $34.4M | $32.1M | $28.1M | $22.0M |
| Operating expenses | $68.8M | $61.0M | $95.3M | $66.4M | $43.2M |
| Operating income | −$68.8M | −$61.0M | −$92.7M | −$62.1M | −$40.4M |
| Net income | −$61.4M | −$52.8M | −$71.1M | −$58.2M | −$55.3M |
| Basic EPSper diluted share | -$2.73 | -$12.03 | -$16.01 | -$2.23 | -$19.00 |
| Diluted EPSper diluted share | -$2.73 | -$12.03 | -$16.01 | -$2.23 | -$19.00 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 6, 2025Form 4 | Lu Timothy KCEO | SellCommon Stock | 545 | $4.36 | $2.4K | 82.1K |
| Feb 6, 2025Form 4 | Rajangam KanyaPres. & Chief Med. & Dev. Off. | SellCommon Stock | 182 | $4.37 | $795.34 | 8.6K |
| Feb 4, 2025Form 4 | Lu Timothy KCEO | SellCommon Stock | 3.9K | $4.07 | $16.0K | 82.6K |
| Feb 4, 2025Form 4 | Rajangam KanyaPres. & Chief Med. & Dev. Off. | SellCommon Stock | 1.3K | $4.07 | $5.3K | 8.8K |
| Dec 9, 2024Form 4 | Bayer US Holding LP +3TenPercentOwner | BuyWarrant · derivative | 3.33M | — | — | 3.33M |